SAS announced today that Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. pharmaceutical company, has selected SAS Solutions OnDemand: Drug Development as a technology platform for clinical development. With SAS OnDemand, DSPA will have a globally accessible, fully regulatory compliant repository for all of its clinical data.
The SAS OnDemand service has allowed DSPA to move quickly, with limited internal resources, in creating its centralized SAS development environment. By letting SAS handle all system provisioning and deployment activities, DSPA resources are free to focus on other mission critical business activities.
SAS Solutions OnDemand: Drug Development is a cost-effective alternative to an enterprise SAS Drug Development implementation, with all embedded enterprise-level content management and analytical capabilities. SAS, through its OnDemand solution, directly supports all hardware and software installation, system administration, validation and maintenance, freeing DSPA from these burdensome responsibilities.
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy